Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates
06:47pm, Thursday, 02'nd Nov 2023
Cytokinetics (CYTK) came out with a quarterly loss of $1.35 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.28 per share a year ago.
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Wednesday, 01'st Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferen
Cytokinetics exploring options after receiving takeover interest - Bloomberg News
02:26pm, Tuesday, 31'st Oct 2023
Heart diseases-focused drug developer Cytokinetics is weighing options after receiving takeover interest, Bloomberg News reported on Tuesday, citing people familiar with the matter.
Cytokinetics to Announce Third Quarter Results on November 2, 2023
04:00pm, Monday, 23'rd Oct 2023
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at 4:0
Cytokinetics (CYTK) Soars 11.4%: Is Further Upside Left in the Stock?
09:01am, Monday, 09'th Oct 2023
Cytokinetics (CYTK) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increas
The 3 Best Mid-Cap Stocks to Buy Now: September 2023
04:29pm, Thursday, 07'th Sep 2023
Banking on the Goldilocks narrative, targeting the best mid-cap stocks centers mostly on balance. If you go the small-capitalization route, you'll benefit from maximum upside potential.
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Thursday, 07'th Sep 2023
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor confere
Cytokinetics, Incorporated (CYTK) Q2 2023 Earnings Call Transcript
11:23pm, Thursday, 03'rd Aug 2023
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Re
Cytokinetics (CYTK) Reports Q2 Loss, Misses Revenue Estimates
06:46pm, Thursday, 03'rd Aug 2023
Cytokinetics (CYTK) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $0.23 per share a year ago.
Cytokinetics to Announce Second Quarter Results on August 3, 2023
04:00pm, Thursday, 27'th Jul 2023
SOUTH SAN FRANCISCO, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 3, 2023 at 4:00
Cytokinetics to Participate in Upcoming Investor Conferences
04:00pm, Thursday, 01'st Jun 2023
SOUTH SAN FRANCISCO, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferen
Cytokinetics, Incorporated (CYTK) Q1 2023 Earnings Call Transcript
11:20pm, Thursday, 04'th May 2023
Cytokinetics, Incorporated (NASDAQ:CYTK ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Diane Weiser - Senior Vice President of Corporate Communications & Investor Relat
Cytokinetics (CYTK) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Thursday, 04'th May 2023
Cytokinetics (CYTK) came out with a quarterly loss of $1.38 per share versus the Zacks Consensus Estimate of a loss of $1.24. This compares to loss of $1.02 per share a year ago.
Cytokinetics to Announce First Quarter Results on May 4, 2023
04:00pm, Thursday, 20'th Apr 2023
SOUTH SAN FRANCISCO, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 4, 2023 at 4:00 PM
Cytokinetics (CYTK) Dips 20% so Far in 2023 on Setbacks
01:41pm, Monday, 10'th Apr 2023
Cytokinetics (CYTK) declines 20% in the year so far as it suffers a regulatory setback for its NDA for omecamtiv mecarbil.
